Atorvastatin in Patients with Type 2 Diabetes Mellitus Undergoing Hemodialysis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of cardiovascular events in persons with type 2 diabetes mellitus. However, the benefit of statins in such patients receiving hemodialysis, who are at high risk for cardiovascular disease and death, has not been examined. METHODS: We conducted a multicenter, randomized, double-blind, prospective study of 1255 subjects with type 2 diabetes mellitus receiving maintenance hemodialysis who were randomly assigned to receive 20 mg of atorvastatin per day or matching placebo. The primary end point was a composite of death from cardiac causes, nonfatal myocardial infarction, and stroke. Secondary end points included death from all causes and all cardiac and cerebrovascular events combined. RESULTS: After four weeks of treatment, the median level of low-density lipoprotein cholesterol was reduced by 42 percent among patients receiving atorvastatin, and among those receiving placebo it was reduced by 1.3 percent. During a median follow-up period of four years, 469 patients (37 percent) reached the primary end point, of whom 226 were assigned to atorvastatin and 243 to placebo (relative risk, 0.92; 95 percent confidence interval, 0.77 to 1.10; P=0.37). Atorvastatin had no significant effect on the individual components of the primary end point, except that the relative risk of fatal stroke among those receiving the drug was 2.03 (95 percent confidence interval, 1.05 to 3.93; P=0.04). Atorvastatin reduced the rate of all cardiac events combined (relative risk, 0.82; 95 percent confidence interval, 0.68 to 0.99; P=0.03, nominally significant) but not all cerebrovascular events combined (relative risk, 1.12; 95 percent confidence interval, 0.81 to 1.55; P=0.49) or total mortality (relative risk, 0.93; 95 percent confidence interval, 0.79 to 1.08; P=0.33). CONCLUSIONS: Atorvastatin had no statistically significant effect on the composite primary end point of cardiovascular death, nonfatal myocardial infarction, and stroke in patients with diabetes receiving hemodialysis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intensive glucose control (A1C levels <7% in T2D and <7.5% in T1D) in several clinical trials was found to reduce the risk of incident albuminuria (A2) and DKD onset.70,78,90,406–410”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“Finally, in the UKPDS, wherein intensive treatment led to a mean end point A1C of 7.0%, hypoglycemia occurred in 1.8% of insulin-treated persons per year in the intensive group vs 0.7% of conventionally treated persons per year.407”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [407]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“CKD is strongly associated with dyslipidemia, and CVD remains the leading cause of mortality among patients with CKD.25,26,28”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
In the citing paper
“However, because of the gaps in data and negative study results, uncertainty exists over the benefits of applying proven CVD therapy in the general population to the CKD population, especially in patients with advanced kidney disease.”
From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [26]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
Clinical epidemiology of cardiovascular disease in chronic renal disease
Foley, R., Parfrey, P., & Sarnak, M. (1998) · American Journal of Kidney Diseases · doi:10.1053/ajkd.1998.v32.pm9820470 · Cited by 3,958
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia
Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00600.x · Cited by 1,179
Research works printed but not linked: 2
- 1994, Lancet, 344, 1383
- Takayama F, 1998, Cell Mol Biol, 44, 1101
Cited by
Items 1,001–1,005 of 1,005
Pedersen, T. X., Bro, S., Andersen, M. H., Etzerodt, M., Jauhiainen, M., Moestrup, S., & Nielsen, L. B. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.04.041 · Cited by 22
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
on behalf of the SHARP Collaborative Group, Reith, C., Staplin, N., Herrington, W. G., Stevens, W., Emberson, J., Haynes, R., Mafham, M., Armitage, J., Cass, A., et al. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0545-2 · Cited by 16
Novel strategies for managing dyslipidemia: treatment beyond statins
Ling, H., Burns, T. L., & Hilleman, D. E. (2012) · Postgraduate Medicine · doi:10.3810/pgm.2012.11.2612 · Cited by 10
Kim, J., Hoang, T., Kim, J.-M., Bu, S. Y., Choi, J.-H., Park, E., Lee, S.-M., Park, E., Min, J. Y., Lee, I. S., et al. (2020) · Nutrients · doi:10.3390/nu12103203 · Cited by 8
Metadata
- Authors
- Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E.
- Affiliations
- University of Würzburg (DE)
- Medical University of Graz (AT)
- University Medical Center Freiburg (DE)
- München Klinik Schwabing (DE)
- Pfizer (Germany) (DE)
- Heidelberg University (DE)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-07-21
- Volume
- 353
- Issue
- 3
- Pages
- 238-248
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2110601215
- Cited by
- 2,614
- References
- 30
- Citations by year
- 2026: 74 · 2025: 51 · 2024: 66 · 2023: 76 · 2022: 90 · 2021: 92 · 2020: 97 · 2019: 110 · 2018: 96 · 2017: 104 · 2016: 110 · 2015: 132 · 2014: 153 · 2013: 162 · 2012: 185
- FWCI
- 135.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- atorvastatin, type 2 diabetes, hemodialysis, statins, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, LDL cholesterol, end-stage renal disease
- MeSH terms
- Atorvastatin, Aged, Cerebrovascular Disorders, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Heart Diseases, Renal Dialysis, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Pyrroles, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.